中国在专家关注的情况下调查其政府采购系统中的药物质量问题。 China investigates drug quality issues in its government procurement system amid expert concerns.

中国国家卫生安全管理局(NHSA)在医疗专家提出关切后,正在调查与政府采购的药物可能存在的质量问题。 China’s National Healthcare Security Administration (NHSA) is investigating potential quality issues with government-procured drugs after concerns were raised by medical experts. 调查侧重于集中的药物采购系统,该系统旨在降低药物价格,但因药物效力不一致而遭到批评。 The investigation focuses on the centralized drug procurement system, which aims to reduce drug prices but has faced criticism over inconsistent drug efficacy. NHSA将与卫生和药物管制当局合作,邀请保健专业人员报告任何问题,以确保药物质量和保护公共健康。 NHSA will work with health and drug regulatory authorities, inviting healthcare professionals to report any issues to ensure drug quality and protect public health.